Shoulder Innovations, Inc. (SI) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Analysis Summary
Trailing-twelve-month margins: gross margin 77.3%, operating margin -58.5%, net margin -58.3%.
At the current price of $17.89, SI has negative trailing earnings (P/E not meaningful) and an ROE of -25.67%. Market capitalisation stands at $371M.
Balance sheet quality for SI: current ratio of 11.1, net cash position of $109.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $17.89 |
| Market Cap | $371M |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 2.92 |
| EV / EBITDA | -12.26 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -25.67% |
| Return on Invested Capital | -25.25% |
| Return on Assets | -23.05% |
| Gross Margin | 77.34% |
| Operating Margin | -58.53% |
| Net Margin | -58.33% |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 10.71 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SI | Shoulder Innovations, Inc. | $371M | 2.92 | -25.7% | |
| ALC | Alcon Inc. | $32.2B | 51.85 | 1.52 | |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | |||
| 0A05.L | Medacta Group S.A. | $2.3B |
Price Performance
| 1 month | -15.33% |
| 3 months | -3.56% |
| Year-to-date | +25.10% |
| 1 year | +20.55% |
52-Week Range
| 52-week High | $24.60 |
| 52-week Low | $10.92 |
| Avg Volume (90d) | 114K |
Related companies: AARD · ASMB · ENTA · EPRX · INGN · MDXH · NAUT
Explore sector: Healthcare · Medical - Specialties
More sections of SI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks